Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry

Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) and its ligand PD-L1 have proven to be efficient cancer therapies in a subset of patients. From all the patients with various cancer types, only 20% have a positive response. Being able to distinguish patients that do express...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Dora Mugoli Chigoho, Quentin Lecocq, Robin Maximilian Awad, Karine Breckpot, Nick Devoogdt, Marleen Keyaerts, Vicky Caveliers, Catarina Xavier, Jessica Bridoux
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2021-06-01
Edice:	Pharmaceuticals
Témata:	cancer nanobodies PD-L1 site-specific PET gallium-68
On-line přístup:	https://www.mdpi.com/1424-8247/14/6/550
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!